(VIANEWS) – Allegiant Travel Company (ALGT), Medpace Holdings (MEDP), Catalyst Pharmaceuticals (CPRX) are the highest sales growth and return on equity stocks on this list.

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. Allegiant Travel Company (ALGT)

77.7% sales growth and 16.06% return on equity

Allegiant Travel Company, a leisure travel company, provides travel services and products to residents of under-served cities in the United States.

Allegiant Travel Company’s sales growth this year is expected to be 70% and 27.5% for next year.

Year-on-year quarterly revenue growth grew by 101.5%, now sitting on 1.71B for the twelve trailing months.

Volume

Today’s last reported volume for Allegiant Travel Company is 240660 which is 11.13% above its average volume of 216540.

Allegiant Travel Company’s sales growth for the next quarter is 77.7%. The company’s growth estimates for the ongoing quarter and the next is 205.4% and 157.3%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.06%.

Volatility

Allegiant Travel Company’s last day, last week, and last month’s current intraday variation average was 2.14%, 1.85%, and 1.88%, respectively.

Allegiant Travel Company’s highest amplitude of average volatility was 3.12% (day), 4.84% (last week), and 4.65% (last month), respectively.

Allegiant Travel Company’s Stock Yearly Top and Bottom Value

Allegiant Travel Company’s stock is valued at $174.74 at 19:22 EST, way below its 52-week high of $271.29 and way above its 52-week low of $155.34.

Allegiant Travel Company’s Moving Average

Allegiant Travel Company’s worth is under its 50-day moving average of $179.34 and below its 200-day moving average of $190.54.

2. Medpace Holdings (MEDP)

24.9% sales growth and 20.68% return on equity

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia.

Medpace Holdings’s sales growth this year is anticipated to be 23.8% and 15.3% for next year.

Year-on-year quarterly revenue growth grew by 18.8%, now sitting on 1.14B for the twelve trailing months.

Volume

Today’s last reported volume for Medpace Holdings is 392956 which is 17.46% above its average volume of 334535.

Medpace Holdings’s sales growth for the next quarter is 24.9%. The company’s growth estimates for the ongoing quarter and the next is 10.5% and 25.5%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.68%.

Medpace Holdings’s Stock Yearly Top and Bottom Value

Medpace Holdings’s stock is valued at $150.15 at 19:22 EST, way under its 52-week high of $231.00 and above its 52-week low of $136.80.

Medpace Holdings’s Moving Average

Medpace Holdings’s value is way below its 50-day moving average of $176.10 and way under its 200-day moving average of $186.84.

3. Catalyst Pharmaceuticals (CPRX)

15.6% sales growth and 49.72% return on equity

Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States.

Catalyst Pharmaceuticals’s sales growth this year is expected to be 14.1% and 20.3% for next year.

Year-on-year quarterly revenue growth grew by 22.8%, now sitting on 126.9M for the twelve trailing months.

Volume

Today’s last reported volume for Catalyst Pharmaceuticals is 733558 which is 37.37% below its average volume of 1171400.

Catalyst Pharmaceuticals’s sales growth for the next quarter is 15.6%. The company’s growth estimates for the present quarter and the next is a negative 75.6% and negative 0%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 49.72%.

Volatility

Catalyst Pharmaceuticals’s last day, last week, and last month’s current intraday variation average was 3.07%, 2.58%, and 3.34%, respectively.

Catalyst Pharmaceuticals’s highest amplitude of average volatility was 4.28% (day), 4.54% (last week), and 5.98% (last month), respectively.

Catalyst Pharmaceuticals’s Stock Yearly Top and Bottom Value

Catalyst Pharmaceuticals’s stock is valued at $7.48 at 19:22 EST, under its 52-week high of $7.58 and way higher than its 52-week low of $3.27.

Catalyst Pharmaceuticals’s Moving Average

Catalyst Pharmaceuticals’s worth is way above its 50-day moving average of $6.53 and way higher than its 200-day moving average of $5.51.

4. Amphenol Corporation (APH)

12.6% sales growth and 26.12% return on equity

Amphenol Corporation, together with its subsidiaries, primarily designs, manufactures, and markets electrical, electronic, and fiber optic connectors in the United States, China, and internationally.

Amphenol Corporation’s sales growth this year is anticipated to be 21.7% and 6.2% for next year.

Year-on-year quarterly revenue growth grew by 27.7%, now sitting on 9.11B for the twelve trailing months.

Volume

Today’s last reported volume for Amphenol Corporation is 4072270 which is 63.6% above its average volume of 2489040.

Amphenol Corporation’s sales growth is a negative 0% for the present quarter and 12.6% for the next. The company’s growth estimates for the ongoing quarter and the next is 14.8% and 14.3%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 26.12%.

Volatility

Amphenol Corporation’s last day, last week, and last month’s current intraday variation average was 0.39%, 1.65%, and 1.66%, respectively.

Amphenol Corporation’s highest amplitude of average volatility was 3.97% (day), 3.20% (last week), and 2.79% (last month), respectively.

Amphenol Corporation’s Stock Yearly Top and Bottom Value

Amphenol Corporation’s stock is valued at $72.54 at 19:22 EST, way under its 52-week high of $83.18 and way above its 52-week low of $58.58.

Amphenol Corporation’s Moving Average

Amphenol Corporation’s worth is below its 50-day moving average of $77.11 and higher than its 200-day moving average of $72.22.

5. Zoetis (ZTS)

8% sales growth and 47.76% return on equity

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally.

Zoetis’s sales growth this year is anticipated to be 15.1% and 8.3% for next year.

Year-on-year quarterly revenue growth grew by 11.4%, now sitting on 7.62B for the twelve trailing months.

Volume

Today’s last reported volume for Zoetis is 1921910 which is 16.68% below its average volume of 2306890.

Zoetis’s sales growth is a negative 0% for the current quarter and 8% for the next. The company’s growth estimates for the present quarter and the next is 0.9% and 11%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 47.76%.

Volatility

Zoetis’s last day, last week, and last month’s current intraday variation average was 4.65%, 2.99%, and 1.58%, respectively.

Zoetis’s highest amplitude of average volatility was 3.91% (day), 3.07% (last week), and 2.49% (last month), respectively.

Zoetis’s Stock Yearly Top and Bottom Value

Zoetis’s stock is valued at $181.39 at 19:22 EST, way under its 52-week high of $231.91 and way above its 52-week low of $141.41.

Zoetis’s Moving Average

Zoetis’s value is way under its 50-day moving average of $213.52 and under its 200-day moving average of $190.29.

LEAVE A REPLY

Please enter your comment!
Please enter your name here